 |
 Video: What is a Stock Split?
|
|
|
| Arvinas is a clinical-stage biotechnology company. Co.'s investigational clinical stage programs include: ARV-471, which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; bavdegalutamide (ARV-110), which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC; and ARV-766, which is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. According to our Arvinas stock split history records, Arvinas has had 0 splits. | |
|
Arvinas (ARVN) has 0 splits in our Arvinas stock split history database.
Looking at the Arvinas stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arvinas shares, starting with a $10,000 purchase of ARVN, presented on a split-history-adjusted basis factoring in the complete Arvinas stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/28/2018 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$16.87 |
|
| End price/share: |
$32.82 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
94.55% |
|
| Average Annual Total Return: |
12.62% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$19,455.70 |
|
| Years: |
5.60 |
|
|
|
|
|
